Interleukin-6 and cachexia in ApcMin/+ mice

被引:225
作者
Baltgalvis, Kristen A. [1 ,3 ]
Berger, Franklin G. [2 ,3 ]
Pena, Maria Marjorette O. [2 ,3 ]
Davis, J. Mark [1 ]
Muga, Stephanie J. [4 ]
Carson, James A. [1 ,3 ]
机构
[1] Univ S Carolina, Dept Exercise Sci, Publ Hlth Res Ctr, Integrat Muscle Biol Lab, Columbia, SC 29208 USA
[2] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA
[3] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA
[4] Med Univ S Carolina, Dept Cellular & Mol Pharmacol, Charleston, SC 29425 USA
关键词
cachexia; colorectal cancer; inflammation; polyps; STAT-3;
D O I
10.1152/ajpregu.00716.2007
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The Apc(Min/+) mouse has a mutation in the Apc tumor suppressor gene and develops intestinal polyps, beginning at 4 wk of age. This mouse develops cachexia by 6 mo, characterized by significant loss of muscle and fat tissue. The purpose of the present study was to determine the role of circulating interleukin-6 (IL-6) and the polyp burden for the development of cachexia in Apc(Min/+) mice. At 26 wk of age, mice exhibiting severe cachectic symptoms had a 61% decrease in gastrocnemius muscle weight, complete loss of epididymal fat, a 10-fold increase in circulating IL-6 levels, and an 89% increase in intestinal polyps compared with mildly cachectic animals. Apc(Min/+)/IL-6(-/-) mice did not lose gastrocnemius muscle mass or epididymal fat pad mass while overall polyp number decreased by 32% compared with Apc(Min/+) mice. Plasmid-based IL-6 overexpression in Apc(Min/+)/IL-6(-/-) mice led to a decrease in gastrocnemius muscle mass and epididymal fat pad mass and increased intestinal polyp burden. IL-6 overexpression did not induce cachexia in non-tumor-bearing mice. These data demonstrate that IL-6 is necessary for the onset of adipose and skeletal muscle wasting in the Apc(Min/+) mouse and that circulating IL-6 can regulate Apc(Min/+) mouse tumor burden.
引用
收藏
页码:R393 / R401
页数:9
相关论文
共 46 条
  • [1] Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle
    Al-Khalili, Lubna
    Bouzakri, Karim
    Glund, Stephan
    Lonnqvist, Fredrik
    Koistinen, Heikki A.
    Krook, Anna
    [J]. MOLECULAR ENDOCRINOLOGY, 2006, 20 (12) : 3364 - 3375
  • [2] al-Majid S, 2001, Biol Res Nurs, V2, P186, DOI 10.1177/109980040100200304
  • [3] Exercise, cachexia, and cancer therapy: A molecular rationale
    Ardies, CM
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2002, 42 (02): : 143 - 157
  • [4] Cytokines in the pathogenesis of cancer cachexia
    Argilés, JM
    Busquets, S
    López-Soriano, FJ
    [J]. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2003, 6 (04) : 401 - 406
  • [5] Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen
    Barton, BE
    Murphy, TF
    [J]. CYTOKINE, 2001, 16 (06) : 251 - 257
  • [6] Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456
  • [7] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [8] Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: Relevance for tumour progression
    Brozek, W
    Bises, G
    Girsch, T
    Cross, HS
    Kaiser, HE
    Peterlik, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (15) : 2347 - 2354
  • [9] SOCS3 negatively regulates IL-6 signaling in vivo
    Croker, BA
    Krebs, DL
    Zhang, JG
    Wormald, S
    Willson, TA
    Stanley, EG
    Robb, L
    Greenhalgh, CJ
    Förster, I
    Clausen, BE
    Nicola, NA
    Metcalf, D
    Hilton, DJ
    Roberts, AW
    Alexander, WS
    [J]. NATURE IMMUNOLOGY, 2003, 4 (06) : 540 - 545
  • [10] Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting
    Davis, TW
    Zweifel, BS
    O'Neal, JM
    Heuvelman, DM
    Abegg, AL
    Hendrich, TO
    Masferrer, JL
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03) : 929 - 934